Migraine CGRP Therapies: Sex-Based Efficacy, Hormonal Influences, and Clinical Implications

DOI: 10.5281/zenodo.16371119

ABSTRACT

This episode investigates the role of sex differences in migraine and how they affect response to a revolutionary class of drugs—CGRP-targeted therapies. We unpack the underlying biology, including the impact of estrogen, the sensitivity of female trigeminal systems, and the broader concept of sexual dimorphism in pain processing. The conversation compares monoclonal antibodies (MABs) and small-molecule CGRP receptor antagonists (the “gepants”), highlighting why acute gepant treatments may be significantly more effective in women than men. We examine real-world efficacy data, FDA findings, pharmacokinetics, and the urgent need for sex-disaggregated clinical trial design. From foundational science to clinical practice, this episode offers a compelling case for precision medicine in migraine care.

CLINICS & SERVICES

Book an appointment:

https://appointments.conciercare.net/#/400NeurologyService

Read more in our CONCIERCARE newsroom feature:

https://health.conciercare.net/news/post/10.5281.cjn.16371119

OBJECTIVES

1. What accounts for the higher prevalence and severity of migraine in females?

2. How do CGRP-targeted monoclonal antibodies (MABs) and gepants work differently?

3. What is the “estrogen withdrawal hypothesis” and how does it relate to migraine triggers in women?

4. What do pooled analyses reveal about the differing efficacy of acute gepants in men vs. women?

5. Are there pharmacokinetic or safety differences in CGRP therapies based on sex?

6. What explains the comparable efficacy of preventive CGRP therapies across sexes?

7. Why are most CGRP trials underpowered to detect sex-specific effects, especially in men?

8. How can future clinical trials and basic science better address sex-based biology in migraine research?

Join the conversation—Have you or someone you know experienced different responses to migraine treatments? Share your thoughts or questions below.

ABOUT US

CONCIERCARE is a health system pioneering personalized, ethical, and evidence-driven care across medical specialties. Learn more at: https://health.conciercare.net

COPYRIGHT & DISCLAIMER

https://health.conciercare.net/news/post/10.5281.cjn.16371119 - Funding & Ethical Disclosures

#Migraine, #CGRP, #SexDifferences, #PrecisionMedicine, #Neurology, #Hormones, #Estrogen, #Pharmacogenomics, #MABs, #Gepants, #TrigeminalSystem, #PainMedicine, #WomensHealth

If you are in crisis, please call 911 or call, text or chat with the Suicide and Crisis Lifeline at 988, or contact the Crisis Text Line by texting TALK to 741741, or visit https://988lifeline.org/.The 988 Lifeline is available 24/7/365. YOUR CONVERSATIONS ARE FREE AND CONFIDENTIAL.

Genetic Testing in Depression: Promises, Pitfalls, and the Path Forward

DOI: 10.5281/zenodo.16113884

ABSTRACT

This podcast episode explores the growing field of genetic testing in depression—unpacking both its exciting promises and sobering limitations. It delves into how pharmacogenomics (PGX) and polygenic risk scores (PRS) are being marketed to personalize antidepressant treatment and predict risk for major depressive disorder (MDD). We examine the strength (and weakness) of current scientific evidence, regulatory positions from the FDA and APA, and the real-world clinical impact—or lack thereof—seen in major studies like GUIDED and PRIMECARE. The episode also tackles the ethical dilemmas of data privacy, discrimination, and informed consent, especially as these tools edge closer to mainstream psychiatry. Ultimately, the conversation calls for caution, equity, and evidence-based integration of these powerful technologies.

CLINICS & SERVICES

Book an appointment:

https://appointments.conciercare.net/#/400NeurologyService

Read more in the CONCIERCARE newsroom:

https://health.conciercare.net/news/post/10.5281.cjmg.16240973

OBJECTIVES

1. What is the current role of genetic factors in major depressive disorder (MDD)?

2. How do pharmacogenomic (PGX) tests aim to guide antidepressant selection and dosing?

3. What does the evidence say about the clinical utility of PGX testing, especially from studies like GUIDED and PRIMECARE?

4. How do polygenic risk scores (PRS) work, and why are they not yet ready for clinical prediction in individuals?

5. What do major regulatory and psychiatric bodies like the FDA and APA recommend regarding these tests?

6. Why is transparency in test algorithms and independent funding critical to trust and clinical adoption?

7. What ethical, legal, and social risks do genetic tests in psychiatry pose—particularly regarding stigma, insurance, and family privacy?

8. How might future advances in systems biology and multi-omics bring us closer to truly personalized psychiatric care?

Join the conversation—Have questions or thoughts about genetic testing for depression? Share them in the comments below.

ABOUT US

CONCIERCARE is a patient-first health system working at the intersection of medicine, ethics, and innovation. Learn more at: https://health.conciercare.net

COPYRIGHT & DISCLAIMER

https://health.conciercare.net/news/post/10.5281.cjmg.16240973 - Funding & Ethical Disclosures

#GeneticTesting, #Pharmacogenomics, #Depression, #MentalHealth, #MDD, #PGX, #PRS, #PersonalizedMedicine, #Bioethics, #FDA, #APA, #Neuropsychiatry, #HealthEquity

If you are in crisis, please call 911 or call, text or chatwith the Suicide and Crisis Lifeline at 988 or contact the Crisis Text Line by texting TALK to 741741 or visit https://988lifeline.org/. The 988 Lifeline is available 24/7/365. YOUR CONVERSATIONS ARE FREE ANDCONFIDENTIAL.

Antidepressants and Female Sexual Function: Mechanisms,Risks, and Clinical Solutions

DOI: 10.5281/zenodo.16239004

ABSTRACT

This episode explores how antidepressants—especially SSRIs,SNRIs, and NDRIs—uniquely affect sexual function in females, from adolescence through adulthood. It dives deep into the neurochemical underpinnings of drug-induced sexual dysfunction, known as AIDS (Antidepressant-Induced Sexual Dysfunction), and addresses the serious long-term risk of Post-SSRI Sexual Dysfunction (PSSD). The discussion outlines pharmacological mechanisms, symptom profiles, clinical challenges, and ethical considerations, particularly when treating adolescent girls. It also presents evidence-based strategies for prevention and treatment, including switching antidepressants, augmentation therapies, and non-pharmacologic interventions like exercise and sex therapy. Emphasis is placed on patient-centered care, informed consent, and preserving sexual health as a core component of well-being.

CLINICS & SERVICES

Book an appointment:

https://appointments.conciercare.net/#/400NeurologyService

Learn more in our CONCIERCARE newsroom feature: https://health.conciercare.net/news/post/10.5281.cjpmh.16239004

OBJECTIVES

1. How does depression itself impact sexual function inwomen and girls?

2. What are the mechanisms behind sexual side effects ofSSRIs, SNRIs, and NDRIs?

3. How do serotonin, dopamine, and norepinephrine interactto influence sexual health?

4. What is the true incidence of antidepressant-inducedsexual dysfunction in females?

5. How does bupropion compare to serotonergic agents interms of sexual side effects?

6. What is Post-SSRI Sexual Dysfunction (PSSD), and why isit a serious clinical concern?

7. What are the special risks associated with prescribing toadolescent girls?

8. What management strategies (drug switches, augmentation, behavioral therapies) are supported by evidence?

Do you have insights, questions, or experiences related tosexual side effects of antidepressants? Drop a comment below and let's talk.

ABOUT US

CONCIERCARE is a patient-focused health system advancingspecialty care through education, access, and advocacy. Learn more at: https://health.conciercare.net

COPYRIGHT & DISCLAIMER

https://health.conciercare.net/news/post/10.5281.cjpmh.16239004 - Funding & Ethical Disclosures

#Antidepressants #SexualHealth #PSSD #SSRIs #SNRIs#Bupropion #WomensHealth #AdolescentMentalHealth #Neuropharmacology #InformedConsent #Psychiatry #PrecisionMedicine #publichealth #podcast #healthcare #women